Abstract
Summary
Due to estrogen deficiency, postmenopausal women may suffer from an imbalance in bone metabolism that leads to bone fractures. Isoflavones, a type of phytoestrogen, have been suggested to improve bone metabolism and increase bone mass. Therefore, isoflavones are increasingly recognized as a promising natural alternative to hormone replacement therapy for postmenopausal women who face a heightened risk of osteoporosis and are susceptible to bone fractures.
Purpose
This study aimed to evaluate the efficacy of isoflavone interventions on bone mineral density (BMD) in postmenopausal women by means of systematic review and meta-analysis.
Methods
The electronic database searches were performed on PubMed, Embase, Scopus, and Cochrane Library databases, covering literature up to April 20, 2023. A random-effects model was used to obtain the main effect estimates, with a mean difference (MD) and its 95% confidence interval (CI) as the effect size summary. The risk of bias assessment was conducted using the Risk of Bias 2 (RoB2) tool.
Results
A total of 63 randomized controlled trials comparing isoflavone interventions (n = 4,754) and placebo (n = 4,272) were included. The results indicated that isoflavone interventions significantly improved BMD at the lumbar spine (MD = 0.0175 g/cm2; 95% CI, 0.0088 to 0.0263, P < 0.0001), femoral neck (MD = 0.0172 g/cm2; 95% CI, 0.0046 to 0.0298, P = 0.0073), and distal radius (MD = 0.0138 g/cm2; 95% CI, 0.0077 to 0.0198, P < 0.0001) in postmenopausal women. Subgroup analysis showed that the isoflavone intervention was effective for improving BMD when the duration was ≥ 12 months and when the intervention contained genistein of at least 50 mg/day.
Conclusion
This systematic review and meta-analysis suggests that isoflavone interventions, especially those containing genistein of at least 50 mg/day, can effectively enhance BMD in postmenopausal women.
Similar content being viewed by others
Data availability
All data used to support the findings of this study are available from the corresponding author upon reasonable request.
References
Jeremiah MP, Unwin BK, Greenawald MH, Casiano VE (2015) Diagnosis and management of osteoporosis. Am Fam Physician 92:261–268
WHO Scientific Group on the Prevention and Management of Osteoporosis (2003) Prevention and management of osteoporosis: report of a WHO scientific group. World Health Organization
Boschitsch EP, Durchschlag E, Dimai HP (2017) Age-related prevalence of osteoporosis and fragility fractures: real-world data from an Austrian Menopause and Osteoporosis Clinic. Climacteric J Int Menopause Soc 20:157–163. https://doi.org/10.1080/13697137.2017.1282452
Cheng C-H, Chen L-R, Chen K-H (2022) Osteoporosis due to hormone imbalance: An overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. Int J Mol Sci 23:1376. https://doi.org/10.3390/ijms23031376
Center JR, Nguyen TV, Schneider D et al (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet Lond Engl 353:878–882. https://doi.org/10.1016/S0140-6736(98)09075-8
Feldstein A, Elmer PJ, Orwoll E et al (2003) Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 163:2165–2172. https://doi.org/10.1001/archinte.163.18.2165
Rondanelli M, Faliva MA, Barrile GC et al (2021) Nutrition, physical activity, and dietary supplementation to prevent bone mineral density loss: A food pyramid. Nutrients 14:74. https://doi.org/10.3390/nu14010074
Body J-J, Bergmann P, Boonen S et al (2011) Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporos Int 22:2769–2788. https://doi.org/10.1007/s00198-011-1545-x
Reginster JY, Neuprez A, Beaudart C et al (2014) Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis. Drugs Aging 31:413–424. https://doi.org/10.1007/s40266-014-0179-z
Tu KN, Lie JD, Wan CKV et al (2018) Osteoporosis: A review of treatment options. Pharm Ther 43:92–104
Cosman F (2014) Anabolic and antiresorptive therapy for osteoporosis: Combination and sequential approaches. Curr Osteoporos Rep 12:385–395. https://doi.org/10.1007/s11914-014-0237-9
Chen JS, Sambrook PN (2012) Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol 8:81–91. https://doi.org/10.1038/nrendo.2011.146
Levin VA, Jiang X, Kagan R (2018) Estrogen therapy for osteoporosis in the modern era. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 29:1049–1055. https://doi.org/10.1007/s00198-018-4414-z
Marjoribanks J, Farquhar C, Roberts H et al (2017) Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017:CD004143. https://doi.org/10.1002/14651858.CD004143.pub5
Wu L, Ling Z, Feng X et al (2017) Herb medicines against osteoporosis: Active compounds & relevant biological mechanisms. Curr Top Med Chem 17:1670–1691. https://doi.org/10.2174/1568026617666161116141033
Geller SE, Studee L (2006) Soy and red clover for mid-life and aging. Climacteric 9:245–263. https://doi.org/10.1080/13697130600736934
Barańska A, Kanadys W, Bogdan M, et al (2022) The role of soy isoflavones in the prevention of bone loss in postmenopausal women: A systematic review with meta-analysis of randomized controlled trials. J Clin Med 11. https://doi.org/10.3390/jcm11164676
Kanadys W, Barańska A, Błaszczuk A et al (2021) Effects of soy isoflavones on biochemical markers of bone metabolism in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials. Int J Environ Res Public Health 18:5346. https://doi.org/10.3390/ijerph18105346
Harahap IA, Suliburska J (2022) An overview of dietary isoflavones on bone health: The association between calcium bioavailability and gut microbiota modulation. Mater Today Proc 63:S368–S372. https://doi.org/10.1016/j.matpr.2022.03.549
Wong WW, Lewis RD, Steinberg FM et al (2009) Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial. Am J Clin Nutr 90:1433–1439. https://doi.org/10.3945/ajcn.2009.28001
Ye Y-B, Tang X-Y, Verbruggen MA, Su Y-X (2006) Soy isoflavones attenuate bone loss in early postmenopausal Chinese women. Eur J Nutr 45:327–334. https://doi.org/10.1007/s00394-006-0602-2
Arcoraci V, Atteritano M, Squadrito F et al (2017) Antiosteoporotic activity of genistein aglycone in postmenopausal women: Evidence from a post-hoc analysis of a multicenter randomized controlled trial. Nutrients 9:179. https://doi.org/10.3390/nu9020179
Moher D, Shamseer L, Clarke M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1. https://doi.org/10.1186/2046-4053-4-1
Rohatgi A (2022) Web based tool to extract data from plots, images, and maps. WebPlotDigitizer: Version 4.6. Pacifica, California, USA. https://automeris.io/WebPlotDigitizer
Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.14898
Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH (2019) Cochrane Handbook for Systematic Reviews of Interventions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Completing ‘Summary of findings’ tables and grading the certainty of the evidence, 2nd edn. Wiley, Chichester, pp 375–402
Deeks JJ, Higgins JPT, Altman D (2019) Cochrane Handbook for Systematic Reviews ofInterventions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Analysing data and undertaking meta-analyses, 2nd edn. Wiley, Chichester, pp 241–284
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634. https://doi.org/10.1136/bmj.315.7109.629
Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14:135. https://doi.org/10.1186/1471-2288-14-135
Higgins JPT, Li T, Deeks JJ (2019) Cochrane Handbook for Systematic Reviews of Interventions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Choosing effect measures and computing estimates of effect, 2nd edn. Wiley, Chichester, pp 143–176
Agnusdei D, Adami S, Cervetti R et al (1992) Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. Bone Miner 19(Suppl 1):S43-48. https://doi.org/10.1016/0169-6009(92)90865-b
Melis GB, Paoletti AM, Bartolini R et al (1992) Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium. Bone Miner 19:S49–S56. https://doi.org/10.1016/0169-6009(92)90866-C
Passeri M, Biondi M, Costi D et al (1992) Effect of ipriflavone on bone mass in elderly osteoporotic women. Bone Miner 19(Suppl 1):S57-62. https://doi.org/10.1016/0169-6009(92)90867-d
Kovács AB (1994) Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis. Agents Actions 41:86–87. https://doi.org/10.1007/BF01986400
Maugeri D, Panebianco P, Russo MS et al (1994) Ipriflavone-treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years. Arch Gerontol Geriatr 19:253–263. https://doi.org/10.1016/0167-4943(94)00571-0
Valente M, Bufalino L, Castiglione GN et al (1994) Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 54:377–380. https://doi.org/10.1007/BF00305522
Agnusdei D, Gennari C, Bufalino L (1995) Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 5:462–466. https://doi.org/10.1007/BF01626609
Ushiroyama T, Okamura S, Ikeda A, Ueki M (1995) Efficacy of ipriflavone and 1α vitamin D therapy for the cessation of vertebral bone loss. Int J Gynecol Obstet 48:283–288. https://doi.org/10.1016/0020-7292(94)02280-C
Melis GB, Paoletti AM, Cagnacci A (1996) Ipriflavone prevents bone loss in postmenopausal women. Menopause 3:27
Adami S, Bufalino L, Cervetti R et al (1997) Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 7:119–125. https://doi.org/10.1007/BF01623686
Agnusdei D, Bufalino L (1997) Efficacy of ipriflavone in established osteoporosis and long-term safety. Calcif Tissue Int 61(Suppl 1):S23-27. https://doi.org/10.1007/s002239900381
Agnusdei D, Crepaldi G, Isaia G et al (1997) A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int 61:142–147. https://doi.org/10.1007/s002239900312
de Aloysio D, Gambacciani M, Altieri P et al (1997) Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 11:289–293. https://doi.org/10.3109/09513599709152548
Gambacciani M, Ciaponi M, Cappagli B et al (1997) Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. Maturitas 28:75–81. https://doi.org/10.1016/s0378-5122(97)00059-5
Gennari C, Adami S, Agnusdei D et al (1997) Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. Calcif Tissue Int 61(Suppl 1):S19-22. https://doi.org/10.1007/s002239900380
Nozaki M, Hashimoto K, Inoue Y et al (1998) Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet 62:69–75. https://doi.org/10.1016/s0020-7292(98)00068-x
Potter SM, Baum JA, Teng H et al (1998) Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68:1375S-1379S. https://doi.org/10.1093/ajcn/68.6.1375S
Ohta H, Komukai S, Makita K et al (1999) Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass. Horm Res 51:178–183. https://doi.org/10.1159/000023354
Alekel DL, Germain AS, Peterson CT et al (2000) Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 72:844–852. https://doi.org/10.1093/ajcn/72.3.844
Alexandersen P, Toussaint A, Christiansen C et al (2001) Ipriflavone in the treatment of postmenopausal osteoporosisa randomized controlled trial. JAMA 285:1482–1488. https://doi.org/10.1001/jama.285.11.1482
Katase K, Kato T, Hirai Y et al (2001) Effects of ipriflavone on bone loss following a bilateral ovariectomy and menopause: a randomized placebo-controlled study. Calcif Tissue Int 69:73–77. https://doi.org/10.1007/s00223-001-0017-2
Morabito N, Crisafulli A, Vergara C et al (2002) Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res Off J Am Soc Bone Miner Res 17:1904–1912. https://doi.org/10.1359/jbmr.2002.17.10.1904
Chen Y-M, Ho SC, Lam SSH et al (2003) Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 88:4740–4747. https://doi.org/10.1210/jc.2003-030290
Uesugi T, Toda T, Okuhira T, Chen J-T (2003) Evidence of estrogenic effect by the three-month-intervention of isoflavone on vaginal maturation and bone metabolism in early postmenopausal women. Endocr J 50:613–619. https://doi.org/10.1507/endocrj.50.613
Atkinson C, Compston JE, Day NE et al (2004) The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 79:326–333. https://doi.org/10.1093/ajcn/79.2.326
Harkness LS, Fiedler K, Sehgal AR et al (2004) Decreased bone resorption with soy isoflavone supplementation in postmenopausal women. J Womens Health 2002 13:1000–1007. https://doi.org/10.1089/jwh.2004.13.1000
Kreijkamp-Kaspers S, Kok L, Grobbee DE et al (2004) Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 292:65–74. https://doi.org/10.1001/jama.292.1.65
Lydeking-Olsen E, Beck-Jensen J-E, Setchell KDR, Holm-Jensen T (2004) Soymilk or progesterone for prevention of bone loss–a 2 year randomized, placebo-controlled trial. Eur J Nutr 43:246–257. https://doi.org/10.1007/s00394-004-0497-8
Arjmandi BH, Lucas EA, Khalil DA et al (2005) One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr J 4:8. https://doi.org/10.1186/1475-2891-4-8
Huang H-Y, Yang H-P, Yang H-T et al (2006) One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. J Nutr Biochem 17:509–517. https://doi.org/10.1016/j.jnutbio.2006.01.003
Wu J, Oka J, Higuchi M et al (2006) Cooperative effects of isoflavones and exercise on bone and lipid metabolism in postmenopausal Japanese women: a randomized placebo-controlled trial. Metabolism 55:423–433. https://doi.org/10.1016/j.metabol.2005.10.002
Evans EM, Racette SB, Van Pelt RE et al (2007) Effects of soy protein isolate and moderate exercise on bone turnover and bone mineral density in postmenopausal women. Menopause N Y N 14:481–488. https://doi.org/10.1097/01.gme.0000243570.78570.f7
Marini H, Minutoli L, Polito F et al (2007) Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med 146:839–847. https://doi.org/10.7326/0003-4819-146-12-200706190-00005
Wu J, Oka J, Ezaki J et al (2007) Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause N Y N 14:866–874. https://doi.org/10.1097/gme.0b013e3180305299
Zhang G, Qin L, Shi Y (2007) Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J Bone Miner Res Off J Am Soc Bone Miner Res 22:1072–1079. https://doi.org/10.1359/jbmr.070405
Brink E, Coxam V, Robins S et al (2008) Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study. Am J Clin Nutr 87:761–770. https://doi.org/10.1093/ajcn/87.3.761
Marini H, Bitto A, Altavilla D et al (2008) Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. J Clin Endocrinol Metab 93:4787–4796. https://doi.org/10.1210/jc.2008-1087
Marini H, Minutoli L, Polito F et al (2008) OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration. J Bone Miner Res Off J Am Soc Bone Miner Res 23:715–720. https://doi.org/10.1359/jbmr.080201
Powles TJ, Howell A, Evans DG et al (2008) Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause Int 14:6–12. https://doi.org/10.1258/MI.2007.007033
Atteritano M, Mazzaferro S, Frisina A et al (2009) Genistein effects on quantitative ultrasound parameters and bone mineral density in osteopenic postmenopausal women. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 20:1947–1954. https://doi.org/10.1007/s00198-009-0883-4
Kenny AM, Mangano KM, Abourizk RH et al (2009) Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial. Am J Clin Nutr 90:234–242. https://doi.org/10.3945/ajcn.2009.27600
Radhakrishnan G, Rashmi, Agarwal N, Vaid NB (2009) Evaluation of isoflavone rich soy protein supplementation for ostmenopausal therapy. Pak J Nutr 8:1009–1017. https://doi.org/10.3923/pjn.2009.1009.1017
Vupadhyayula PM, Gallagher JC, Templin T et al (2009) Effects of soy protein isolate on bone mineral density and physical performance indices in postmenopausal women–a 2-year randomized, double-blind, placebo-controlled trial. Menopause N Y N 16:320–328. https://doi.org/10.1097/gme.0b013e3181844893
Alekel DL, Van Loan MD, Koehler KJ et al (2010) The soy isoflavones for reducing bone loss (SIRBL) study: a 3-y randomized controlled trial in postmenopausal women. Am J Clin Nutr 91:218–230. https://doi.org/10.3945/ajcn.2009.28306
Zhang X, Li S-W, Wu J-F et al (2010) Effects of ipriflavone on postmenopausal syndrome and osteoporosis. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 26:76–80. https://doi.org/10.3109/09513590903184159
Cho S-H, Jang J-H, Yoon JY et al (2011) Effects of a safflower tea supplement on antioxidative status and bone markers in postmenopausal women. Nutr Res Pract 5:20–27. https://doi.org/10.4162/nrp.2011.5.1.20
Choquette S, Riesco É, Cormier É et al (2011) Effects of soya isoflavones and exercise on body composition and clinical risk factors of cardiovascular diseases in overweight postmenopausal women: a 6-month double-blind controlled trial. Br J Nutr 105:1199–1209. https://doi.org/10.1017/S0007114510004897
Levis S, Strickman-Stein N, Ganjei-Azar P et al (2011) Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Arch Intern Med 171:1363–1369. https://doi.org/10.1001/archinternmed.2011.330
Shedd-Wise KM, Alekel DL, Hofmann H et al (2011) The soy isoflavones for reducing bone loss study: 3-Yr Effects on pQCT bone mineral density and strength measures in postmenopausal women. J Clin Densitom 14:47–57. https://doi.org/10.1016/j.jocd.2010.11.003
Tousen Y, Ezaki J, Fujii Y et al (2011) Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women: a pilot randomized, placebo-controlled trial. Menopause N Y N 18:563–574. https://doi.org/10.1097/gme.0b013e3181f85aa7
Gui J-C, Brašić JR, Liu X-D et al (2012) Bone mineral density in postmenopausal Chinese women treated with calcium fortification in soymilk and cow’s milk. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 23:1563–1570. https://doi.org/10.1007/s00198-012-1895-z
Tai TY, Tsai KS, Tu ST et al (2012) The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 23:1571–1580. https://doi.org/10.1007/s00198-011-1750-7
Chi X-X, Zhang T (2013) The effects of soy isoflavone on bone density in north region of climacteric Chinese women. J Clin Biochem Nutr 53:102–107. https://doi.org/10.3164/jcbn.13-37
Chilibeck PD, Vatanparast H, Pierson R et al (2013) Effect of exercise training combined with isoflavone supplementation on bone and lipids in postmenopausal women: a randomized clinical trial. J Bone Miner Res Off J Am Soc Bone Miner Res 28:780–793. https://doi.org/10.1002/jbmr.1815
Lappe J, Kunz I, Bendik I et al (2013) Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study. Eur J Nutr 52:203–215. https://doi.org/10.1007/s00394-012-0304-x
Orsatti FL, Nahas EAP, Nahas-Neto J et al (2013) Efeito do treinamento contrarresistência e isoflavona na densidade mineral óssea em mulheres na pós-menopausa. Rev Bras Cineantropometria Desempenho Hum 15:726–736. https://doi.org/10.5007/1980-0037.2013v15n6p726
Clifton-Bligh PB, Nery M-L, Clifton-Bligh RJ et al (2015) Red clover isoflavones enriched with formononetin lower serum LDL cholesterol-a randomized, double-blind, placebo-controlled study. Eur J Clin Nutr 69:134–142. https://doi.org/10.1038/ejcn.2014.207
Thorup AC, Lambert MN, Kahr HS et al (2015) Intake of Novel Red Clover Supplementation for 12 Weeks Improves Bone Status in Healthy Menopausal Women. Evid-Based Complement Altern Med ECAM 2015:689138. https://doi.org/10.1155/2015/689138
Lambert MNT, Thybo CB, Lykkeboe S et al (2017) Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trial. Am J Clin Nutr 106:909–920. https://doi.org/10.3945/ajcn.117.153353
Li L, Sun M, Sun J et al (2019) The effect of dried beancurd on bone mineral density in postmenopausal Chinese women: A 2-Year randomized controlled trial. Calcif Tissue Int 105:573–581. https://doi.org/10.1007/s00223-019-00604-2
Warriner AH, Patkar NM, Curtis JR et al (2011) Which fractures are most attributable to osteoporosis? J Clin Epidemiol 64:46–53. https://doi.org/10.1016/j.jclinepi.2010.07.007
Greendale GA, Sowers M, Han W et al (2012) Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women’s Health Across the Nation (SWAN). J Bone Miner Res Off J Am Soc Bone Miner Res 27:111–118. https://doi.org/10.1002/jbmr.534
Riggs BL, Khosla S, Melton LJ (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763–773. https://doi.org/10.1359/jbmr.1998.13.5.763
Ji MX, Yu Q (2015) Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med 1:9–13. https://doi.org/10.1016/j.cdtm.2015.02.006
Nardi A, Ventura L, Rossini M, Ramazzina E (2010) The importance of mechanics in the pathogenesis of fragility fractures of the femur and vertebrae. Clin Cases Miner Bone Metab 7:130–134
Tanaka S, Adachi T, Kuroda T et al (2014) New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide. Bone Res 2:14043. https://doi.org/10.1038/boneres.2014.43
Kenkre JS, Bassett J (2018) The bone remodelling cycle. Ann Clin Biochem 55:308–327. https://doi.org/10.1177/0004563218759371
Wei P, Liu M, Chen Y, Chen D-C (2012) Systematic review of soy isoflavone supplements on osteoporosis in women. Asian Pac J Trop Med 5:243–248. https://doi.org/10.1016/S1995-7645(12)60033-9
Hirattanapun E, Koonrungsesomboon N, Teekachunhatean S (2018) Variability of isoflavone content in soy milk products commercially available in Thailand. J Health Sci Med Res 36:117–126
Wu Z, Liu L (2022) The protective activity of genistein against bone and cartilage diseases. Front Pharmacol 13:1016981. https://doi.org/10.3389/fphar.2022.1016981
Nikander E, Metsä-Heikkilä M, Ylikorkala O, Tiitinen A (2004) Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer. J Clin Endocrinol Metab 89:1207–1212. https://doi.org/10.1210/jc.2003-031166
Liu J, Ho SC, Su Y et al (2009) Effect of long-term intervention of soy isoflavones on bone mineral density in women: a meta-analysis of randomized controlled trials. Bone 44:948–953. https://doi.org/10.1016/j.bone.2008.12.020
Sansai K, Na Takuathung M, Khatsri R et al (2020) Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 31:1853–1864. https://doi.org/10.1007/s00198-020-05476-z
Hu Q, Long C, Wu D et al (2020) The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis. Pharmacol Res 159:104860. https://doi.org/10.1016/j.phrs.2020.104860
Shams-White MM, Chung M, Fu Z et al (2018) Animal versus plant protein and adult bone health: A systematic review and meta-analysis from the National Osteoporosis Foundation. PLoS One 13:e0192459. https://doi.org/10.1371/journal.pone.0192459
Qiu S, Ma Y, Jiang C (2020) Isoflavone combined with exercise on bone mineral density in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials. J Chin Med Assoc JCMA 83:678–685. https://doi.org/10.1097/JCMA.0000000000000365
Lambert MNT, Hu LM, Jeppesen PB (2017) A systematic review and meta-analysis of the effects of isoflavone formulations against estrogen-deficient bone resorption in peri- and postmenopausal women. Am J Clin Nutr 106:801–811. https://doi.org/10.3945/ajcn.116.151464
Ricci E, Cipriani S, Chiaffarino F et al (2010) Soy isoflavones and bone mineral density in perimenopausal and postmenopausal Western women: a systematic review and meta-analysis of randomized controlled trials. J Womens Health 2002 19:1609–1617. https://doi.org/10.1089/jwh.2010.2021
Ma D-F, Qin L-Q, Wang P-Y, Katoh R (2008) Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials. Clin Nutr Edinb Scotl 27:57–64. https://doi.org/10.1016/j.clnu.2007.10.012
Akhlaghi M, Ghasemi Nasab M, Riasatian M, Sadeghi F (2020) Soy isoflavones prevent bone resorption and loss, a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 60:2327–2341. https://doi.org/10.1080/10408398.2019.1635078
Taku K, Melby MK, Takebayashi J et al (2010) Effect of soy isoflavone extract supplements on bone mineral density in menopausal women: meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr 19:33–42
Song F, Khan KS, Dinnes J, Sutton AJ (2002) Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 31:88–95. https://doi.org/10.1093/ije/31.1.88
Acknowledgements
This research work was partially supported by Chiang Mai University, and by CMU Proactive Researcher, Chiang Mai University [grant number 844/2566].
Funding
None.
Author information
Authors and Affiliations
Contributions
Conceptualization: NK, MN, ST. Methodology: NK, RI, MN, WS, ND. Validation: RI, MN. Formal analysis: RI, WS. Investigation: RI, MN. Writing – original draft: RI, NK. Writing – review & editing: MN, ST, WS. Visualization: RI, NK. Supervision: NK, ST. Project administration: NK.
Corresponding author
Ethics declarations
Conflict of interest
Ratchanon Inpan, Mingkwan Na Takuathung, Wannachai Sakuludomkan, Nahathai Dukaew, Supanimit Teekachunhatean, and Nut Koonrungsesomboon declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Inpan, R., Na Takuathung, M., Sakuludomkan, W. et al. Isoflavone intervention and its impact on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int 35, 413–430 (2024). https://doi.org/10.1007/s00198-023-06944-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-023-06944-y